HR
DNLI icon

Howe & Rusling’s Denali Therapeutics DNLI Stock Holding History

Howe & Rusling’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-125
Closed -$2K – 827
2020
Q1 		$2K Sell
125
-6
-5% -$125 ﹤0.01% 629
2019
Q4 		$2K Hold
131
– – ﹤0.01% 667
2019
Q3 		$2K Hold
131
– – ﹤0.01% 674
2019
Q2 		$3K Sell
131
-6
-4% -$134 ﹤0.01% 596
2019
Q1 		$3K Buy
137
+71
+108% +$1.49K ﹤0.01% 604
2018
Q4 		$1K Buy
+66
New +$1.2K ﹤0.01% 727

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Howe & Rusling's DNLI Position: Q2 2020 in Review

Howe & Rusling sold out of Denali Therapeutics (DNLI) in Q2 2020, closing a stake of 125 shares — an estimated $2K sold.

Howe & Rusling first reported a position in DNLI in Q4 2018 and held it in 6 quarters. The position peaked at $3K in Q2 2019. 148 funds tracked by Wall St. Rank hold DNLI as of Q2 2020.

  • Howe & Rusling reported no remaining Denali Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Howe & Rusling sold 125 Denali Therapeutics shares in Q2 2020, an estimated $2K.
  • Howe & Rusling first reported a position in Denali Therapeutics in Q4 2018 and held it in 6 quarters.
  • Howe & Rusling's Denali Therapeutics position peaked at $3K in Q2 2019.
  • 148 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2020.

Based on Howe & Rusling's 13F filing for Q2 2020, filed 15 Jul 2020.